Abstract
Aim: This multicenter, retrospective study evaluates the clinical benefit (CB) of bevacizumab, alone or in combination, in recurrent gliomas (RG). Patients & methods: The CB was measured as a reduction of corticosteroid dosage and an improvement ≥20 points in the Karnofsky Performance Status lasting ≥3 months. Results: We collected data of 197 RG patients. A CB was observed in 120, patients without significant differences between patients treated with bevacizumab alone or in combination. The rate of patients who achieved a CB and free from progression at 1 year was 21.5 versus 1.4% in patients who did not report CB. Conclusion: The majority of RG patients treated with bevacizumab reported CB. Moreover, patients with CB showed improved survival.
| Original language | English |
|---|---|
| Pages (from-to) | 1717-1727 |
| Number of pages | 11 |
| Journal | Future Oncology |
| Volume | 15 |
| Issue number | 15 |
| DOIs | |
| Publication status | Published - May 1 2019 |
Fingerprint
Keywords
- bevacizumab
- clinical benefit
- glioma
Cite this
Villani, V., Fabi, A., Tanzilli, A., Pasqualetti, F., Lombardi, G., Vidiri, A., Gonnelli, A., Molinari, A., Cantarella, M., Bellu, L., Terrenato, I., Carosi, M., Maschio, M., Telera, S. M., Carapella, C. M., Cognetti, F., Paiar, F., Zagonel, V., & Pace, A. (2019). A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: Clinical benefit is a plausible end point? Future Oncology, 15(15), 1717-1727. https://doi.org/10.2217/fon-2018-0826